Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

Kapeleris, J; Müller Bark, J; Ranjit, S; Irwin, D; Hartel, G; Warkiani, ME; Leo, P; O'Leary, C; Ladwa, R; O'Byrne, K; Hughes, BGM; Punyadeera, C

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

Kapeleris, J Müller Bark, J Ranjit, S Irwin, D Hartel, G Warkiani, ME Leo, P O'Leary, C Ladwa, R O'Byrne, K Hughes, BGM Punyadeera, C

Permalink

Publisher:: ELSEVIER SCI LTD
Publication Type:: Journal Article
Citation:: Heliyon, 2022, 8, (7), pp. e09971
Issue Date:: 2022-07

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.46 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kapeleris, J
dc.contributor.author	Müller Bark, J
dc.contributor.author	Ranjit, S
dc.contributor.author	Irwin, D
dc.contributor.author	Hartel, G
dc.contributor.author	Warkiani, ME
dc.contributor.author	Leo, P
dc.contributor.author	O'Leary, C
dc.contributor.author	Ladwa, R
dc.contributor.author	O'Byrne, K
dc.contributor.author	Hughes, BGM
dc.contributor.author	Punyadeera, C
dc.date.accessioned	2023-03-12T22:52:50Z
dc.date.available	2022-07-13
dc.date.available	2023-03-12T22:52:50Z
dc.date.issued	2022-07
dc.identifier.citation	Heliyon, 2022, 8, (7), pp. e09971
dc.identifier.issn	2405-8440
dc.identifier.issn	2405-8440
dc.identifier.uri	http://hdl.handle.net/10453/167083
dc.description.abstract	BACKGROUND: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12-18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients. METHODS: CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T0) and 3-months post-treatment (T1). CTCs were enriched using a spiral microfluidic chip and characterised by immunofluorescence. ctDNA was assessed using an UltraSEEK® Lung Panel. Kaplan-Meier plots were generated to investigate the contribution of the presence of CTC/CTC clusters and cfDNA for PFS. Cox proportional hazards analysis compared time to progression versus CTC/CTC cluster counts and cfDNA levels. RESULTS: Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T0. At T1, CTCs were found in 7 out of 18 patients, and CTC clusters in 1 out of the 18 patients. At T0, CTC presence and the combination of CTC cluster counts with cfDNA levels were associated with shorter PFS, p = 0.0261, p = 0.0022, respectively. CONCLUSIONS: Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	ELSEVIER SCI LTD
dc.relation.ispartof	Heliyon
dc.relation.isbasedon	10.1016/j.heliyon.2022.e09971
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.
dc.type	Journal Article
utslib.citation.volume	8
utslib.location.activity	England
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-03-12T22:52:46Z
pubs.issue	7
pubs.publication-status	Published online
pubs.volume	8
utslib.citation.issue	7

Abstract:

BACKGROUND: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12-18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients. METHODS: CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T0) and 3-months post-treatment (T1). CTCs were enriched using a spiral microfluidic chip and characterised by immunofluorescence. ctDNA was assessed using an UltraSEEK® Lung Panel. Kaplan-Meier plots were generated to investigate the contribution of the presence of CTC/CTC clusters and cfDNA for PFS. Cox proportional hazards analysis compared time to progression versus CTC/CTC cluster counts and cfDNA levels. RESULTS: Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T0. At T1, CTCs were found in 7 out of 18 patients, and CTC clusters in 1 out of the 18 patients. At T0, CTC presence and the combination of CTC cluster counts with cfDNA levels were associated with shorter PFS, p = 0.0261, p = 0.0022, respectively. CONCLUSIONS: Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/167083